Metagenomi Therapeutics, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Metagenomi Therapeutics, Inc. (MGX) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$783.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-10
- Metagenomi Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$553.00K.
- Metagenomi Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$230.00K.
- Metagenomi Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$486.00K, a 141.75% decline year-over-year.
- Metagenomi Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$1.14M, a 228.81% decline year-over-year.
- Metagenomi Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$4.31M, a 285.67% decline from fiscal 2024.
- Metagenomi Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $2.32M, a 113.12% increase from fiscal 2023.
- Metagenomi Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $1.09M.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$553.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$783.00K 10-Q · filed 2026-08-10 | -$1.27M derived: sum of 3 quarters · filed 2026-08-10 | -$2.41M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$230.00K 10-Q · filed 2026-05-11 | -$716.00K derived: sum of 2 quarters · filed 2026-05-11 | -$1.86M derived: sum of 3 quarters · filed 2026-05-11 | -$2.31M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$486.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$1.63M derived: sum of 2 quarters · filed 2026-03-05 | -$2.08M derived: sum of 3 quarters · filed 2026-08-10 | -$4.31M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$1.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$1.59M derived: sum of 2 quarters · filed 2026-08-10 | -$3.83M 10-Q · filed 2025-11-12 | -$2.66M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$450.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$2.69M 10-Q · filed 2026-08-10 | -$1.52M derived: sum of 3 quarters · filed 2026-08-10 | -$638.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$2.24M 10-Q · filed 2026-05-11 | -$1.07M derived: sum of 2 quarters · filed 2026-05-11 | -$188.00K derived: sum of 3 quarters · filed 2026-05-11 | -$852.00K derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $2.05M derived: sum of 2 quarters · filed 2026-03-05 | $1.39M derived: sum of 3 quarters · filed 2026-03-05 | $2.32M 10-K · filed 2026-03-05 |
| 2024-09-30 | $885.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $221.00K derived: sum of 2 quarters · filed 2025-11-12 | $1.16M 10-Q · filed 2025-11-12 | $2.64M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$664.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $274.00K 10-Q · filed 2025-08-12 | $1.75M derived: sum of 3 quarters · filed 2025-08-12 | $1.39M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $938.00K 10-Q · filed 2025-05-13 | $2.42M derived: sum of 2 quarters · filed 2025-05-13 | $2.05M derived: sum of 3 quarters · filed 2025-05-13 | $1.93M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $1.48M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $1.11M derived: sum of 2 quarters · filed 2025-03-17 | $993.00K derived: sum of 3 quarters · filed 2025-03-17 | $1.09M 10-K · filed 2025-03-17 |
| 2023-09-30 | -$368.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$486.00K derived: sum of 2 quarters · filed 2024-11-13 | -$389.00K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | -$118.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$21.00K 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $97.00K 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |